// App-Quantinova.ai

: Cyclophosphamide, Pomalidomide and Dexamethasone Significantly Improves Response over Poma/Dex in Relapsed/Refractory Myeloma Patients Previously Treated with Cyclophosphamide Combination Therapy - Initial Results of the Randomised Multicentre Mukseven Trial

Researchers

Presenter

  • James Croft

Principal Investigators

  • Andrew Hall

  • Katrina Walker

  • Amy L Sherborne

  • Sidra Ellis

  • Amy Price

  • Debbie Sherratt

  • Sadie Reed

  • Charlotte Pawlyn

  • Mamta Garg

  • Kevin Boyd

  • Gordon Cook

  • Sarah R Brown

  • Martin Kaiser

Medical Centers

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • The Royal Marsden Hospital, London, United Kingdom

  • Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom

  • Leicester Royal Infirmary Haematology, Leicester, United Kingdom

  • Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

Outcome

  • N/A

Study Design

  • Randomized

  • Multicenteric

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved